Professor Dr. Nico Lachmann uses novel reactor vessels that can produce human immune cells on a scalable scale. Copyright: ’Marco Oliveira’.
Professor Dr. Nico Lachmann uses novel reactor vessels that can produce human immune cells on a scalable scale. Copyright: 'Marco Oliveira'. MHH researcher Nico Lachmann receives 2.5 million euros for Fraunhofer-Attract group Immune cells and immune cell preparations are playing an increasingly important role in modern medicine.Nico Lachmann, research group leader at the Clinic for Paediatric Pneumology, Allergology and Neonatology at Hannover Medical School (MHH) and researcher of the RESIST Cluster of Excellence, wants to use standardised immune cells to test the efficacy and safety of drugs. For this project, he is also building The Attract working group is based at the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM. Standardised production of mature immune cells. The demand for human immune cells is high and growing daily. So far, however, it has been difficult to provide cells in suitable quantity and quality, because every person - and thus every immune cell donation - is different.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
